Post Approval Study of the Eversense® Continuous Glucose Monitoring
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 273 participants.
Also called NCT03908125
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase
- Not applicable
- Enrolled
- 273 participants
- Sponsor
- Registry
-
NCT03908125
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03908125. Allocation not applicable; no masking; primary purpose diagnostic. Start 2019-03-19 (actual); primary completion 2024-02-01 (actual). Results posted on 2025-06-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Post Approval Study of the Eversense® Continuous Glucose Monitoring
- Acronym
- PAS
- Condition
- Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 1
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Device)
- Eversense® CGM System
- Lead sponsor
- Senseonics, Inc.
Record details
- Record id
cardio:ct-nct03908125- Content hash
44ae49ce7d92e8e078d4d04b3057069f737b71acdca283daf9611484dfb71ee0